Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOD1 | Q9Y239 | 8/20 | 0.69 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.55 |
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.55 |
| ▸ | PLA2G10 | O15496 | 2/20 | 0.54 |
| ▸ | GNPAT | O15228 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | FAAH | O00519 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.48 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.48 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.48 |
| ▸ | PPARG | P37231 | 1/20 | 0.48 |
| ▸ | PPARD | Q03181 | 1/20 | 0.48 |
| ▸ | PPARA | Q07869 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25651310 | 1.00 | NOD1 (0.69) | NOD1PLA2G2CSLC6A5PLA2G10GNPAT | |
| SCHEMBL71687 | 1.00 | NOD1 (0.69) | NOD1PLA2G2CSLC6A5PLA2G10GNPAT | |
| SCHEMBL8292791 | 1.00 | NOD1 (0.69) | NOD1PLA2G2CSLC6A5PLA2G10GNPAT | |
| SCHEMBL29329833 | 1.00 | NOD1 (0.69) | NOD1PLA2G2CSLC6A5PLA2G10GNPAT | |
| SCHEMBL18560506 | 1.00 | NOD1 (0.69) | NOD1PLA2G2CSLC6A5PLA2G10GNPAT | |
| SCHEMBL23601770 | 1.00 | NOD1 (0.69) | NOD1PLA2G2CSLC6A5PLA2G10GNPAT | |
| SCHEMBL18783045 | 1.00 | NOD1 (0.69) | NOD1PLA2G2CSLC6A5PLA2G10GNPAT | |
| SCHEMBL14685779 | 1.00 | NOD1 (0.69) | NOD1PLA2G2CSLC6A5PLA2G10GNPAT | |
| SCHEMBL14725995 | 1.00 | NOD1 (0.69) | NOD1PLA2G2CSLC6A5PLA2G10GNPAT | |
| SCHEMBL18573779 | 0.97 | NOD1 (0.74) | NOD1PLA2G2CSLC6A5PLA2G10GNPAT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4177263-A1 | NOVEL POLYPEPTIDE AND THERAPEUTIC USE THEREOF | Vitalixir (Beijing) Co., Ltd (CN) | 2023-05-10 | — | — | EP | disclosed |
| US-20140315797-A1 | Novel N-Terminally Modified Insulin Derivatives | NOVO NORDISK A/S (DK) | 2014-10-23 | — | — | US | disclosed |
| US-8722849-B2 | Polypeptides | NOVO NORDISK A/S (DK) | 2014-05-13 | — | — | US | disclosed |
| US-8722849-B2 | Polypeptides | NOVO NORDISK A/S (DK) | 2014-05-13 | — | — | US | disclosed |
| US-20130143798-A1 | NOVEL GLUCAGON ANALOGUES | NOVO NORDISK A/S (DK) | 2013-06-06 | — | — | US | disclosed |
| US-20130005646-A1 | POLYPEPTIDES | NOVO NORDISK A/S (DK) | 2013-01-03 | — | — | US | disclosed |
| US-20130005646-A1 | POLYPEPTIDES | NOVO NORDISK A/S (DK) | 2013-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130143798-A1 | NOVEL GLUCAGON ANALOGUES | GLP1R, GCG, IAPP | NOD1 1083/4885PLA2G2C 478/4885SLC6A5 1154/4885 |
| US-20130005646-A1 | POLYPEPTIDES | IAPP, GLP1R, GIPR | NOD1 3819/4885PLA2G2C 1110/4885SLC6A5 3682/4885 |
| US-20140315797-A1 | Novel N-Terminally Modified Insulin Derivatives | IAPP, INSR, IRS1 | NOD1 428/4885PLA2G2C 628/4885SLC6A5 4006/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.